aTYR PHARMA (ATYR) Director Paul Schimmel Receives Award

What Happened Paul Schimmel, a director of aTyr Pharma, received a 50,000-share derivative award on May 11, 2026. The grant is recorded at $0.00 per share (no immediate cash exchanged) and is reported as a derivative/award rather than a purchase or sale.

Key Details

• Transaction date: 2026-05-11; Form 4 filed: 2026-05-13 (timely within the SEC 2-business-day window).
• Transaction type/code: Grant/Award (A) — derivative award (option).
• Shares/units granted: 50,000; reported price: $0.00; reported total value: $0.
• Vesting: The option vests in full on the earlier of (i) May 11, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued board service (per filing footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context This is a non-employee director compensation award (an option-style grant) rather than a market purchase or sale. The grant itself does not represent immediate proceeds — future value depends on the stock price at exercise and fulfillment of the vesting condition. No exercise or sale occurred in this filing.